Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trialJ. Weiß, K. Dragnev, Tibor Csőszi et al.|Annals of Oncology|2019Cited by 173
Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial)Suresh S. Ramalingam, Claude El Kouri, Philippe Pultar et al.|Annals of Oncology|2013Cited by 57
Rhabdoid tumor of the kidneyGiulio J. D’Angio, Rajesh Malik, Audrey E. Evans|Medical and Pediatric Oncology|1988Cited by 20
Trilaciclib (G1T28): A cyclin dependent kinase 4/6 inhibitor, in combination with etoposide and carboplatin (EP) for extensive stage small cell lung cancer (ES-SCLC)—Phase 1b results.Caio Max S. Rocha Lima, Taofeek K. Owonikoko, Patrick J. Roberts et al.|Journal of Clinical Oncology|2017Cited by 9
Immune correlates of talactoferrin alfa in biopsied tumor of relapsed/refractory metastatic non-small cell lung cancer patientsJonathan W. Riess, Heather A. Wakelee, Nupur Bhattacharya et al.|Immunopharmacology and Immunotoxicology|2014Cited by 4